25-06-2020
Gujarat and Tamil Nadu are the other two states that will receive the first batch of the drug which is being marketed under the brand name COVIFOR in India. Telangana's capital Hyderabad, where the drugmaker is based, will also receive the first consignment.
Hetero said a 100-milligram vial of the drug will cost Rs 5,400. The recommended dose for adults and pediatric patients is 200 mg on Day 1 followed by once daily maintenance doses of 100 mg for five days.
The next batch of the drug will be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum and Goa.
On June 21, the Central Drugs Standard Control Organisation gave approval to Hetero Drugs and Cipla to manufacture and market remdesivir. Both the firms have already entered into non-exclusive licensing agreements with Gilead Sciences, which is the patent holder of the drug remdesivir.
Hetero has said the drug, named Covifor, will be available in 100 mg vials (injectable), which has to be administered intravenously in a hospital setting. Hetero Group of Companies MD Vamsi Krishna Bandi told PTI the price of its remdesivir will be in the range of Rs 5,000-6,000 per dose.
NEW Research—First randomised trial of #remdesivir for hospitalised patients who are critically ill with #COVID19 suggests antiviral drug is not associated with significant clinical benefits vs placebo: study of 237 adults from 10 hospitals in Wuhan (1/5) https://t.co/K0h0qj4okw pic.twitter.com/btIH3mTPCg
— The Lancet (@TheLancet) April 29, 2020
Comments
Post a Comment